Year: 2025

HOUSTON, TX, Jan. 10, 2025 (GLOBE NEWSWIRE) — Prairie Operating Co. (Nasdaq: PROP) (the “Company” or “Prairie”) today announced the on-time completion of its initial eight-well Shelduck South pad in the DJ Basin and is set to have production fully online in the first quarter of 2025. The Shelduck pad, together with recent Nickel Road Operating (NRO) acquisition, represents the first phase in Prairie’s 2025 development program. “The on-time completion of the Shelduck South pad is a testament to the hard work of our team and represents a significant step forward in our growth strategy,” said Edward Kovalik, Chairman and CEO of Prairie Operating Co. “In addition to continuing acquisitions, we are now focused on leveraging this momentum to develop our high-quality assets that position us for long-term value creation.” The Shelduck...

NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) — Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Paul M. Ridker, MD, MPH, Eugene Braunwald Professor of Medicine at the Harvard Medical School and Director of the Center for Cardiovascular Disease Prevention at Brigham and Women’s Hospital, has joined Tourmaline’s Cardiovascular Scientific Advisory Board (CV SAB). “We are beyond honored to welcome Dr. Ridker, a luminary in the field who has helped to fundamentally transform our understanding of cardiovascular disease,” said Sandeep Kulkarni, MD, Co-Founder and Chief Executive Officer of Tourmaline. “Dr. Ridker’s many contributions to cardiovascular...

VANCOUVER, British Columbia, Jan. 10, 2025 (GLOBE NEWSWIRE) — Ranchero Gold Corp. (“Ranchero” or the “Company”) (TSX.V:RNCH) is pleased to announce that, further to its press release dated November 15, 2024, it has completed its debt settlement with William Pincus (the “Creditor”), a former Chief Executive Officer of the Company, by issuing 1,136,666 common shares of the Company (the “Shares”) at a deemed issue price of Cdn$0.06 per Share and issuing 330,769 Shares at a deemed issue price of Cdn$0.090697 per Share to the Creditor in respect of past services provided by the Creditor. The Company received disinterested shareholder approval and TSX Venture Exchange approval for the debt settlement. The Shares are subject to a hold period expiring on May 11, 2025 in accordance with applicable securities laws. About Ranchero Gold Ranchero...

LOUISVILLE, Ky., Jan. 10, 2025 (GLOBE NEWSWIRE) — Churchill Downs Incorporated (“CDI” or “the Company”) announced today that the Company will release fourth quarter and full year 2024 financial results after the market closes on Wednesday, February 19, 2025, and host a related conference call to discuss the quarter on Thursday, February 20, 2025, at 9 a.m. ET. Investors and other interested parties may listen to the call by accessing the online, real-time webcast at http://ir.churchilldownsincorporated.com/events.cfm or by registering in advance via teleconference here. Once registration is completed, participants will be provided with a dial-in number containing a personalized conference code to access the call. All participants are encouraged to dial-in 15 minutes prior to the start time. An online replay of the call will be...

Collaboration combines Owkin’s novel AI target discovery and agentic AI expertise with Absci’s leading AI de novo design models to accelerate the discovery and design of potential first-in-class therapeutics VANCOUVER, Wash. and PARIS, Jan. 10, 2025 (GLOBE NEWSWIRE) — Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, and Owkin, a TechBio that uses agentic AI to unlock complex targets for drug discovery, development, and diagnostics, today announced a partnership bringing together two leading AI platforms to rapidly discover and design novel therapeutics for patients. “At Absci, we’re constantly pushing the boundaries of innovation to bring better biologics to patients faster,” said Sean McClain, Founder and CEO of Absci. “By combining Absci’s AI de novo design expertise with Owkin’s world-class...

2024 Portfolio Receipts expected to be approximately $2,800 million, at the upper end of guidance range Exciting development-stage pipeline with potential for peak royalties of >$1.2 billion; multiple key upcoming events, including Phase 3 results for pelacarsen Royalty Pharma to benefit from new product launches in 2025, including Servier’s Voranigo, Bristol Myers Squibb’s Cobenfy, Ascendis’ Yorvipath, Syndax and Incyte’s Niktimvo and Geron’s RyteloNEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) — Royalty Pharma plc (Nasdaq: RPRX) today provided an update on its business performance, including recent key accomplishments, and the full year 2024 outlook for Portfolio Receipts. Pablo Legorreta, Royalty Pharma’s founder and Chief Executive Officer, will discuss these updates on January 14, 2025 as part of a webcast presentation to be...